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Abstract: Scandinavian folk medicine used shark liver oil for the treatment of cancers and 
other ailments based on the rarity of tumors in sharks and their ability to resist infections. 
Shark liver oil is a source of alkylglycerols which have been studied as anti-cancer agents 
in several clinical trials. Moreover, alkylglycerols have been investigated for the treatment 
of radiation induced side effects and for their ability to boost the immune system. Several 
experimental studies have shown the ability of alkylglycerols to open the blood brain 
barrier to facilitate the access of therapeutic drugs to the central nervous system. This 
review covers the most important studies of alkylglycerols in both animals and humans. 
Keywords: alkylglycerols; alkoxyglycerols; bathyl; selachyl; chimyl; ether lipids 
Abbreviations: AKG: alkylglycerols; APC: alkylphosphocholine; AA: arachidonic acid 
bFGF: basic fibroblast growth factor; BBB: blood-brain barrier;   
CEA: Carcino-EmbryonalesAntigen; C-injuries: complex injuries; CK: creatine kinase; 
CNS: central nervous system; DAG: diacylglycerol; DDG: dodecylglycerol;   
DTH: delayed-type hypersensitivity; EA: serum frec-01% egg albumin supplemented 
RPMI medium; ErPC: erucylphosphocholine; ET-16-OCH3: 1-O-hexadecyl-2-metoxy-
glycero-3-phosphatidylcholine; FCS: fetal calf serum; FITC: fluorescein isothiocyanate; 
fMLP: formyl peptide; i.v.: intravenous injection; HDL-C: high-density lipoprotein 
cholesterol; HG: sn-1-O-hexadecylglycerol; I-injuries: total number of injuries;   
MDA: malondialdehyde; MHG: 1-O (2 methoxy) hexadecyl glycerol; MIC: minimal 
inhibitory concentration; MTX: methotrexate; NK: natural killer NO: nitric oxide;   
PAEC: pulmonary arterial endothelial cells; PAF: platelet activating factor;   
PMA: phorbol-12-myristate-13-acetate; PPS-C16 ODN: phosphorothioate-protected 
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oligonucleotides with 1-O-hexadecylglycerol; PUFA: polyunsatured fatty acids;   
SLO: shark liver oil; [Ca2+]i: calcium concentrations; RAS: aphthous stomatitis;   
R-injuries + C-injuries: sum of the injuries; ROS: reactive oxygen species 
 
1. Introduction  
The shark is a member of the Elasmobranch subclass of fish that includes the ratfish 
(Chimaera monstrosa) and the dogfish (name used to designate a variety of shark species). Virtually 
all species of sharks are known to have an extraordinary resistance to the growth of tumors and 
infections. Several reports have indicated an extremely low incidence of cancer in sharks or even that 
no cases of cancer in sharks have been recorded [1,2] but a review performed by Ostrander and his 
colleagues identified a list of solid tumors found in sharks [3]. The emerging hypothesis is that   
n-3-polyunsaturated fatty acids (PUFA) and other shark liver oil (SLO) components may exert   
anti-carcinogenic effects [1]. SLO contains both alkylglycerols (AKG) and squalene and is an ancient 
remedy among the fishermen along the west coast of Norway and Sweden. It has been used for wound 
healing, the treatment of irritations of the respiratory and alimentary tracts and lymphadenopathy. In 
1922 Tsujimoto and Toyama [4] found AKG in SLO and Sir Robert Robinson, a Nobel laureate, first 
synthesized them in 1930 [5]. In natural sources, they are always found esterified with fatty acids. 
Structurally they are alkyl ethers of glycerol (Figure 1). 
Figure 1. Chemical structure of alkylglycerols (AKG). 
 
Brohult and Holmberg [6], using the unsaponifiable portion of different bone marrow fats as well as 
preparations containing esters of AKG in child leukemia observed a maturing effect on the white blood 
cells leading to experiments employing AKG in irradiation leucopenia [7]. In the early 1950s, Brohult 
performed experiments on children with leukemia. She used extracts isolated from calf marrow and 
observed that they were able to stimulate the production of white blood cells. These finding led, in 
1963, to the publication of a thesis on AKG and their use in radiation treatment [8]. This work showed 
that, in patients with uterine cancer, a decrease in white cells and thrombocytes, which usually occurs 
during radiation treatment, is less pronounced if AKG are administered during this treatment. After 
that it was observed that the incidence of injuries following radiation therapy for carcinoma of the 
uterine cervix was significantly decreased when the patients were treated with AKG [9] and that the 
frequency of fistulas was reduced by 47% when AKG were administered prior to radiation 
treatment [10].  
The principal AKG include chimyl (hexadecyl), batyl (octadecyl) and selachyl (octadecyl) ethers. 
Hallgreen et al. [11] reported that glycerol ethers occur in the tissues in the form of diesters and alkyl 
acyl phosphatides. 1-O-Alkylglycerols and 1-O-(2-methoxyalkyl) glycerols were isolated from the Mar. Drugs 2010, 8  
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neutral lipids and phospholipids of human colostrums, human milk, cow’s milk, sheep’s milk, human 
red bone marrow, red cells, blood plasma, and a uterine carcinoma (Table 1).  
Table 1. AKG are glycerol ether lipids that are naturally occurring in hematopoietic (blood 
forming) organs such as bone marrow, spleen and liver but they can also be found in 
neutrophils and in human and cow milk [12,13]. This table shows AKG percentage in 
human bone marrow, human milk and liver oil. The number of carbon atoms in the first 
column refers to the long-chain component of the molecule. The number after the colon 
denotes the number of double bonds. Table adapted from “Biochemical Effects of 
alkoxyglycerols and their use in cancer therapy” [13]. 
Alkylglycerols  Human Bone Marrow  Human Milk  Greenland Shark Liver Oil 
14:0     2.0 
15 
a     0.7 
16:0 29.4  23.9  9.1 
16:1   Trace  10.8 
17 
a  7.6 3.6  3.6 
18:0 24.6  22.8  2.8 
18:1 16.7  33.8  59.4 
18:2   1.4 1.6 
18:3     ? 
19 
a  6.1 2.4  1.5 
20:0 2.9  1.6  
20:1 3.2  2.3 6.2 
22:0 0.7  0.7  
22:1 5.1  3.4 2.2 
24   2.1   
a Both branched and normal chains C15, C17, and C19 are present. 
The authors found that: (1) human colostrum has a higher content of unsubstituted glycerol ethers 
in the neutral lipids than human milk; (2) human milk contains nearly 10 times more unsubstituted 
glycerol ethers than cow’s milk and twice as much as sheep’s milk; (3) the highest percentage of 
unsubstituted glycerol ethers in neutral lipids was found in the human red bone marrow and the uterine 
carcinoma; (4) the methoxy substituted glycerol ethers were both found in the neutral lipids and in the 
phospholipids of all the tissues studied but only in trace quantities; (5) glycerol ethers with 16 and 18 
carbon atoms in the long hydrocarbon chains (16:0 chimyl, 18:0 batyl and 18:1 selachyl alcohol) are 
the principal components of both the unsubstituted and the 2-methoxy-substituted glycerol ethers;  
(6) a poly-unsaturated methoxy substituted glycerol ether, 1-O-(2-ethoxydocosahexaenyl-1) glycerol, 
was found in the neutral lipids and phospholipids of red blood cells (first found in Greenland SLO [14]). 
The authors have also reported several studies on the clinical effectiveness of glycerol ethers:   
(1) batyl alcohol raises the erythrocyte count of both normal rats and those poisoned with benzene;  
(2) optically active and racemic batyl alcohol stimulate erytrhopoesis, thrombopoesis and 
granulopoesis; (3) chymil alcohol stimulates haemopoesis; (4) selachyl alcohol has no haemopoetic 
activity; (5) a high level of glycerol ethers was found in a variety of transplantable tumors in animals Mar. Drugs 2010, 8  
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and in human tumors; (6) 2-methoxy substituted glycerol ethers has antibiotic activity and inhibits the 
dissemination and growth of several experimental tumors in mice. 
Figure 2. Selachyl, chimyl and batyl alcohols chemical structures. 
 
SLO is also rich in squalene, a triterpene that is an intermediate in cholesterol biosynthesis. We can 
also find it in olive oil, palm oil, wheat-germ oil, amaranth oil, and rice bran oil [15]. Squalene is the 
main component of skin surface polyunsaturated lipids as an emollient and antioxidant, and has 
hydration and antitumor activities; it also finds application in topically applied vehicles such as lipid 
emulsions and nanostructured lipid carriers [15]. 1-O-Alkylglycerols are naturally occurring ether-lipids, 
present in human or cow’s milk and in hematopoietic organs, such as bone marrow, spleen and liver 
[11,16]. SLO is rich in AKG and squalene, but contains relatively low amounts of n-3-PUFA. AKG 
may control immune response possibly through modification of platelet activating factor (PAF) and 
diacylglycerol (DAG) production. Squalene enhances antigen presentation and induction of the 
inflammatory response. Moreover, AKG and squalene have antitumor activity that may be based on 
different mechanisms, i.e., induction of apoptosis of neoplastic cells, suppression of signal 
transduction, inhibition of angiogenesis and promotion of transmembrane transport of cytotoxic 
agents. SLO has been found to be useful in the treatment of conditions resulting from an inadequate 
immune response, and in adjunctive treatment of several types of cancer [17].  
It has been shown that AKG can significantly reduce the injuries due to radiation toxicity, 
enhancing the overall survival rate and survival time in irradiated uterine cervical cancer patients [18]. 
Moreover, SLO enriched diets administered to rats with ischemic heart disease and hypertension, 
improve clinical symptoms, anthropometric levels, lipidemic profile and immunological status [19]. 
Nowicki et al. [20] emphasized the protective action of SLO from bacterial and fungal infections 
recommending it for patients suffering from atopic dermatitis. 
Marigny et al. [21] cultured endothelial cells in the presence of 1-O-alkylglycerols resulting in 
inhibition of calcium ionophore and phorbol-12-myristate-13-acetate (PMA) increased endothelial 
permeability. This effect was associated with the production of an ether analogue of DAG described as 
an inhibitor of DAG-induced protein kinase C activation. Mar. Drugs 2010, 8  
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2. Review Criteria 
We have searched Medline for studies involving the use of alkylglycerols with the keywords 
alkylglycerols, alkoxyglycerols, bathyl, selachyl, chymil and ether lipids. The results are categorized 
according to the way these compounds affect cancer, immunity, the blood brain barrier, bacteria and 
fungi, plasmalogens and radiation therapy.  
3. Alkylglycerols Studies 
3.1. Alkylglycerols and immunity 
AKG and alkyl lysophospholipids significantly activate cytotoxic macrophages leading to enhanced 
Fc-receptor mediated phagocytosis and increase humoral immune response and delayed hypesensivity 
reaction [22]. AKG have been shown to stimulate hematopoiesis, erythropoiesis, thrombocytosis and 
granulocytosis in animals [23,24]. 
Sy et al. [25] designed a study to assess the effects of dietary supplementation with AKG in the 
range of 10, 50 and 250 ppm (chymil, batyl and selachyl glycerols solubilized in corn oil in the 
proportion of 30% chimyl, 28% batyl, and 42% selachyl glycerol to resemble the AKG composition in 
human milk) in lactating rats (Sprague-Dawley female rats, 8–10 weeks old) on AKG levels in milk 
and development of certain immune responses in the pups. Concentrations of AKG in milk from the 
dams fed AKG were significantly greater than those of the controls. Peripheral blood granulocytes 
were significantly elevated in pups from the dams fed AKG, but there were no differences in 
peripheral blood lymphocyte numbers. Plasma levels of immunoglobulins were significantly greater 
for IgG and IgM in pups from the dams fed AKG than in the control pups. This study shows that the 
murine milk contains glyceryl ether lipids in amounts comparable to those in human milk; increasing 
the levels of AKG in murine milk, the number of granulocytes in peripheral blood and plasma level of 
immunoglobulins, namely IgM was significantly increased in suckling pups. This study suggests that 
AKG in murine milk play a role in the development of immune response in newborn rat pups. 
Homma et al. [26] treated a mixture of mouse (female BALB/c mice, aged 7–12 weeks) peritoneal 
non-adherent and adherent cells for 30 min with 50 ng dodecylglycerol (DDG)/mL in 10% foetal calf 
serum (FCS) supplemented RPMI-1640 medium. They observed a greatly enhanced ingestion of   
IgG-coated target cells but not IgM-coated target cells with complement. DDG treatment of adherent 
cells (macrophages) alone did not enhance ingestion activity of macrophages. This may be related to a 
signal factor(s) for macrophage activation which is transmitted from non-adherent cells to adherent 
cells during the brief DDG treatment period. Peritoneal cells were treated with 50 ng DDG/mL of a 
serum frec-01% egg albumin supplemented RPMI medium (EA) for 30 min and cultured in EA 
medium for 3 hours to try to identify the signal factor. A very small increase in ingestion activity of 
macrophages was observed. In contrast 30 min treatment of the peritoneal cells in FCS medium 
produced a greatly enhanced activation of macrophages. These observations suggested that a factor(s) 
contained in serum was required for activation of macrophages. Non-adherent cells were treated with 
50 ng DDG in EA medium for 30 min., washed in PBS and cultured in FCS medium for 2 hours. The 
resultant conditioned medium of the DDG treated non-adherent cells was added to adherent cells and 
cultured for 3 hours. A greatly enhanced ingestion activity of macrophages was observed. However Mar. Drugs 2010, 8  
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3  hour cultivation of adherent cells with conditioned medium of the untreated non-adherent cells 
resulted in no enhanced ingestion activity of macrophages. These results indicate that the DDG treated 
non-adherent cells, if serum is present, generate a signal factor for macrophages to develop ingestion 
activity. The authors searched for the serum factor required for activation of macrophages through 
electrophoretic fractionation. FCS was electrophoresed in a starch block. Each fraction was added to 
DDG-treated splenic non-adherent cells in EA medium and cultured for 2 hours. The resultant 
conditioned medium was added to adherent cells for 3 hour cultivation prior to ingestion assay. 
Cultivation of adherent cells with the conditioned medium prepared with fraction no. 7 of 
electrophoresed serum produced a greatly enhanced ingestion activity of macrophages. With fraction 
no. 6, a lesser degree of macrophage activation was observed. No other fraction had significant 
macrophage activation activity. When analyzed by immunoelectrophoresis, fraction no. 7 (also no. 6 
and 8) contained goat anti-bovine immunoreactable material, mainly in the α2-globulin region. This 
study showed that when peritoneal cells (mixture of non-adherent and adherent cells) are treated with 
50 ng DDG/mL in FCS medium for 30 min and washed to remove residual DDG and nonadherent 
cells, the adherent macrophages develop a greatly enhanced ingestion activity after 3 hour cultivation. 
A rapid signal transfer from non-adherent cells to adherent cells must have occurred during a 30 min 
DDG treatment period. Enucleated cell ghosts of splenic non-adherent (B and T) cells by hypotonic 
shock in 1/10 PBS were prepared. The splenic non-adherent cell ghosts were treated with 50 ng DDG/mL 
in EA medium for 30 min, washed in PBS and incubated in α2-globulin (electrophoresed fraction no. 7) 
supplemented EA medium for 2 hours. After removal of the non-adherent cell ghosts, the medium was 
used for 3 hour cultivation of peritoneal adherent cells. A greatly enhanced Fc-receptor mediated 
ingestion activity of macrophages was observed. Therefore, they concluded that a serum component of 
α2-globulin fraction is rapidly modified by pre-existing membranous functions or enzymes of B and 
T cells to yield macrophage activating factor. Concluding, these results show that: (1) α2-globulin 
contains a factor required during cultivation of DDG-treated peritoneal cells for activation of 
macrophages; (2) one of the α2-globulin components is responsible for macrophage activation;   
(3) DBP is the vitamin D3 transport protein and its interaction with macrophages may be a prerequisite 
for macrophage differentiation and macrophage activation and serum DBP in α2-globulin serum 
fraction is a possible serum factor required for macrophage activation; (4) the conditioned media of 
individually DDG treated B and T cells are unable to activate macrophages after 3 hour cultivation of 
adherent cells suggesting that both cell types are involved in transferring activation signal to 
macrophages; (5) cultivation of adherent cells with a mixture of treated B cell conditioned medium and 
treated T cell conditioned medium produced no significant activation of macrophages emphasizing 
that signal transmission among non-adherent cells must have occurred. 
Yamamoto et al. [27] observed that administration of small amounts (10–100 ng) of AKG to mice 
(female BALB/c mice, 7–12 weeks old) greatly enhanced macrophage activation for Fc-mediated 
ingestion activity at the 5th day post treatment. Moreover a low dose, 5 ng/kg DDG (100 ng/mouse) of 
animal body weight is the most effective dosage for macrophage activation. Administration of lower 
concentrations of a longer carbon chained AKG, sn-3-octadecylglycerol (batyl alcohol), to mice 
produced a similar activation of macrophages. In vitro treatment of cultured peritoneal cells, with a 
very low concentration (50 ng/mL) of DDG, activates macrophages in 2–3 hours; whena mixture of 
macrophages and nonadherent (B and T) cells was treated with DDG, a greatly enhanced Fc-mediated Mar. Drugs 2010, 8  
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ingestion was observed at about 3 hour post treatment, suggesting that non-adherent cells contributed 
to the activation of macrophages. When a conditioned medium of DDG-treated B- or T-cells was 
admixed with macrophages and incubated for 3 hours, no significantly enhanced ingestion activity of 
macrophages was observed. Thus, exchange of signalling factor(s) among B- and T-cells was analyzed 
by transferring conditioned media of DDG-treated B- or T-cells to untreated T- or B-cells. When the 
resultant (treated B-cells–untreated T-cells) conditioned medium was admixed with untreated 
macrophages and incubated for 3 hours, a markedly enhanced Fc-mediated ingestion was observed  
(no significant increase in ingestion activity was found in macrophages incubated with the treated  
T-cell–untreated B-cell conditioned medium. The data reported in this study suggest that DDG 
treatment of B-cells triggers initiation of development of macrophage ingestion capacity. DDG-treated 
B-cells initiates macrophage activation processes by releasing and transmitting a signalling factor(s) to 
T-cells, and in turn the T-cells modify the factor or produce a new factor(s) capable of the ultimate 
stimulation of macrophages for ingestion capability. This study emphasizes that DDG application, as a 
chemotherapeutic agent, is due to potentiation of macrophage, i.e., antigen-presenting cells. Treating 
the animals with these agents potentiates host immune systems against cancer activity and citotoxicity 
of malignant cells. 
Yamamoto et al. [28] also observed that in vitro treatment of peritoneal cells (from female BALB/c 
mice, 7–12 weeks of age), with DDG (50 ng DDG/mL) in 10% FCS supplemented medium RPMI-1640 
resulted in a greatly enhanced Fc receptor-mediated phagocytic activity of macrophages. This 
macrophage activation process requires a serum factor in the α2-globulin fraction. The interaction of a 
serum factor with non-adherent cells and modification of the serum factor by B and T cells are 
required for the in vitro activation of macrophages by DDG; purification of this serum factor by 
electrophoresis and by actin affinity chromatography shows to improve its precursor activity; a small 
amount of α-globulin fraction (0.05%, v/v) or purified human DBP (0.026 ng/mL) efficiently supports 
activation of macrophages; purified human DBP can be efficiently converted by DDG-treated 
nonadherent cells to a macrophage-activating factor. Conversion of DBP to the macrophage-activating 
factor in the absence of other serum proteins is very efficient; a minute amount as low as 26 pg/mL of 
purified human DBP can be converted to yield a sufficient amount of macrophage-activating factor to 
achieve activation of macrophages; higher doses of this serum factor yield their correspondingly large 
amounts of the macrophage activating factor, but an excess of the macrophage activating factor does 
not achieve a proportional enhancement of phagocytic activity but rather exhibits suppression of 
macrophage activation. 
Mitre et al. [29] administered 32 g SLO/d to twelve pregnant and then lactating sows (from day 80 
of pregnancy to weaning) to determine the effect on the growth and immune status of their offspring, 
compared with a control group. Sows were vaccinated against Aujeszky’s disease 21 days before term. 
Supplemented sows had higher levels of both erythrocytes and Hb in their blood, and higher 
concentrations of IgG, AKG and n-3 PUFA in their mammary secretions. In piglets from 
supplemented sows, leucocytes and IgG were higher. Supplementation with SLO resulted in an 
increase in Aujeszky antibodies in both blood and colostrum of sows after vaccination, together with 
an increase in Aujeszky antibodies in piglet blood. Dietary supplementation with SLO to gestating and 
lactating sows induced a positive effect on litter immune status associated with a modification of both 
lipid content and immune properties of the mother’s milk.  Mar. Drugs 2010, 8  
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Pedrono et al. [30] studied the effect of natural AKG (AKG species varied according to the alkyl-chain 
length, with composition as follows: 14:0 = 0.7%, 16:0 = 9.1%, 16:1n-7 = 12.5%, 18:1n-9 = 68.1%, 
18:1n-7 = 4.8% and other minor species (<0.1%) = 4.8%) purified from SLO on [
3H]-serotonin release 
from rabbit platelets in vitro. [
3H]-AKG (1 mM) were incorporated into platelet lipids and metabolised 
into phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol. AKG (10 mM) had no 
effect on spontaneous [
3H]-serotonin release, partially inhibited platelet-activating factor and did not 
modify thrombin-induced release. This study shows that AKG inhibit partially and specifically   
PAF-induced platelet stimulation possibly interfering with PAF receptors. 
Homma  et al. [31] reported that a 30 min in vitro treatment of peritoneal cells (mixture of   
non-adherent and adherent cells from BALB/mice, 7–12 weeks of age) with 50 ng/mL of synthetic 
DDG resulted in greatly enhanced Fc-receptor-mediated ingestion activity of macrophages. In this 
study they observed that treatment of adherent cells (macrophages), alone with DDG, produced no 
significant enhancement of macrophage ingestion activity, implying that macrophage activation 
requires a contribution of non-adherent cells. This observation emphasized that a signal factor for 
macrophage activation has to be rapidly transmitted from non-adherent cells to adherent cells during 
the 30 min in vitro treatment of non-adherent and adherent cells. DDG treated non-adherent cells were 
found to generate a macrophage-activating signal factor. Studies with a serum free 0.1% egg   
albumin-supplemented RPMI 1640 medium revealed that a serum factor is essential for macrophage 
activation process. DDG-treated B cells rapidly transmit a factor to untreated T cells which yield the 
ultimate macrophage-activating factor. This signal transmission among these cells for the macrophage 
activation process is too rapid to allow time for synthesis of inducible gene products leading to the 
hypothesis that a serum factor is modified by the pre-existing function of DDG-treated B cells and 
further modified by the pre-existing function of untreated T cells to yield macrophage-activating 
factor. This hypothesis is confirmed by the demonstration that DDG-treated splenic non-adherent cell 
ghosts modify a serum factor to yield macrophage-activating factor. 
Pedrono et al. [32] studied the role of AKG (prepared from Centrophorus squamosus SLO. AKG 
species varied according to the alkyl-chain length, whose composition was as follows: 14:0 = 0.7%, 
16:0 = 9.1%, 16:1n-7 = 12.5%, 18:1n-9 = 68.1%, 18:1n-7 = 4.8% and other minor species = 4.8%) on 
the calcium signalling in Jurkat T-cells, an immortalized line of T lymphocyte cells with the ability to 
produce interleukin-2. AKG induced a dose-dependent increase of cytosolic calcium rate in Jurkat  
T-cells as a function of time (plateau reached after 20 min). When the experiments were performed in 
calcium-free buffer, the AKG response on the rise of intracellular calcium concentration [Ca
2+]i was 
wholly abolished compared with the one in calcium-containing buffer, suggesting that these ether 
lipids were able to induce a calcium influx by the opening of Ca
2+ channels. This study showed that 
verapamil, an inhibitor of L-type VGCC, did not affect [Ca
2+]i rise stimulated by AKG. N-conotoxin, 
known to block N-type VGCC was shown to be able to abolish partially the AKG-activated entry of 
extracellular Ca
2+ (up to 39% of the maximal calcium rise). AKG effect on the modifications in 
membrane potential (Vm) was assessed. Gramicidin, known to induce depolarisation, and AA, shown 
to provoke hyperpolarisation, were employed as controls. AKG evoked plasma membrane 
depolarisation three times higher than gramicidin. Addition of AA evoked hyperpolarisation in these 
cells. Addition of AA after AKG reversed the depolarisation induced by the latter. Moreover, 
successive addition of AKG induced additive increases in plasma membrane depolarisation in Jurkat Mar. Drugs 2010, 8  
 
 
2275
T-cells. Concluding this study shows that AKG are able to increase [Ca
2+]i influx in human Jurkat T-cells 
possibly by modulating the permeability of calcium channels.  
Tchorzewski  et al. [33] proved that supportive treatment with SLO components normalizes 
complement level, natural killer (NK) cells activity and reactive oxygen intermediates production by 
peripheral blood leukocytes of people suffering from active form rheumatoid arthritis.  
Acevedo et al. [34] evaluated the activation activity of AKG on the human histiocytic cell line 
U937 and the murine macrophagic cell line J774 to induce IL-12 and NO respectively, and the 
adjuvant activity of synthetic AKG to stimulate an antibody response (IgG2a-IgG1) against a soluble 
antigen (Ova). AKG stimulated the production of IL-12 and NO regardless of the carbon chain length; 
the levels of IL-12 induced by AKG appeared to be higher than LPS but lower than AFPs2 which is a 
powerful inducer of IL-12; AKG increased IgG levels compared with baseline levels induced by the 
administration of ova adsorbed to alum; the levels of anti-Ova IgG appeared to depend on the chain 
length of AKG; murine Th1 immune responses are associated with IgG2a production by B cells while 
Th2 responses are associated with IgG1 and IgE expression; high levels of IgG2a were also elicited 
when OVA were administered with AKG and AFPs2 as shown by the increase in the IgG2a/IgG1 
ratio; all AKG elicited both Th1 and Th2 antibodies but AKG with longer chain length were associated 
with higher anti-Ova IgG2a production. This study shows that since AKG are able to induce a high 
level of IL-12, a key cytokine for the activation of Th1 responses, they could provide an environment 
for Th1 polarization. Synthetic AKG are effective adjuvants for the standardized antigen, Ova. 
Pamblad et al. [35] designed a study to assess whether various AKG would initiate a functional 
response of human neutrophils or modify responses induced by a formyl peptide (fMLP) in vitro. The 
PAF was the most potent with regard to the ability to produce an oxidative response   
(assessed by cytochrome C reduction and/or chemiluminescence), followed by   
1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine (ET-16-OCH3), a structurally modified ether 
lipid; Lyso-PAF, ET-18-OCH3, batyl- and chimyl alcohols exhibited only a weak activity; PAF was 
also the most efficient lipid conferring a rise of [Ca
2+]i. ET-16-OCH3 and LysoPAF were less potent, 
although maximal [Ca
2+]i levels were similar to that of 0.1 pmoVl fMLP; the kinetics of the calcium 
responses were highly specific for each ether lipid; neutrophils treated with PAF or ET-18-OCH3 and 
subsequently stimulated by fMLP showed an enhancement of the oxidative response. The authors 
concluded that the previously described alkyl lipids are able to stimulate functional response in human 
neutrophils. PAF showed to be, on an equimolar basis, the most potent of tested ether lipids in 
conferring a secretory as well as a [Ca2+]i response. ET-16-OCH3 was also able to stimulate both 
functions. Some of the other phosphatidylcholine-containing ether lipids were associated with a rise of 
[Ca
2+]i, but only with minute or no oxidative responses (LysoPAF > ET-18-OCH3 > M-lyso-PAF). 
CA, BA and M-BA (simple AKG) showed to be only weak stimulants for chemiluminescence. 
Apparently the phosphatidyl group in 3-position is essential for both calcium and oxidative responses 
(showed by LysoPAF and CA and BA). Moreover, the introduction of a methyl group in the 2-position 
is able to increase the tested biological activity (cf. ET-16-OCH3 and ET-18-OCH3 with LysoPAF), 
although the methyl group was less active than the acetyl group (cf. FT-16-OCH3 and ET-18-OCH3 
with PAF). Insertion of a methoxy side-group on the fatty acid in the 1-position reduced the assessed 
biological activity (cf. LysoPAF with M-lysoPAF and BA with M-BA). An acetyl group in the 2-position 
was associated with greater efficacy, as demonstrated by comparisons of PAF with LysoPAF and Mar. Drugs 2010, 8  
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OAG with MPG. Comparisons of PAF and IysoPAF with PPC and SPC, and of BA and CA with 
MPG, suggested that ether compounds were associated with enhanced biological activity. This study 
also showed that some ether lipids induced oxidative as well as [Ca
2+]i responses (PAF, ET-16-OCH3), 
whereas others mainly conferred a [Ca
2+]i rise (LysoPAF, ET-18-OCH3, M-lysoPAF). This suggested 
that a calcium rise is not sufficient by itself to activate the NADPH-oxidase, catalysing conversion of 
oxygen to superoxide ion. Since ether lipids have attracted interest as antitumour agents, ET-18-OCH3 
has been advocated as a bone marrow purging substance, the intake of a mixture of CA, BA, M-BA 
and methoxy-substituted alkyl lipids, similar to M-lysoPAF has been shown to reduce the 5-year 
cervical cancer mortality and also the radiation-induced neutropenia in such patients. Ether lipids have 
also shown to increase blood concentrations of neutrophils and enhance antibody formation 
taken together.  
Lewkowicz et al. [36] studied SLO supplementation with high doses (3.6 g) of squalene, 3.6 g of 
AKG and 750 mg of n-3-PUFA per day in 13 volunteers for 4 weeks. An increased response of 
neutrophils towards bacteria, an increased level of C4 component of complement in blood, the rise of 
total antioxidant status of serum, and the predominance of type 1 cytokine IFN-gamma, TNF-α and IL-2 
production by peripheral blood mononuclear cells after SLO intake were observed. SLO 
supplementation markedly affected lipid metabolism and cholesterol balance too. The authors 
observed an increase of total cholesterol level from 182.92 ± 29.290 mg/dL before oil consumption to 
224.46 ± 62.198 mg/dL after diet rich in oil and noted a decrease of HDL fraction. In all individuals 
metabolism of lipids normalized spontaneously after the end of the experiment. This study showed that 
the main effects of SLO are the result of the biological activity of squalene and 1-O-alkylglycerols. 
Moreover, they noted that the anti-inflammatory effects of n-3-PUFA did not manifest when taken 
together with high doses of squalene and AKG. This study shows that SLO supplementation in high 
doses is beneficial in bacterial, viral and fungal infections although patients with atherosclerosis or 
autoimmune diseases should avoid the consumption of high amounts of SLO. 
Tchorzewski et al. [37] administered nine capsules of Biomarine 570 (an agent extracted from 
Greenland SLO) a day for 30 days to 10 healthy randomly chosen volunteers and observed that 
BioMarine intake increased the C1q level, the CD4/CD8 ratio from 1.3 to 1.8 and polarized Th1/Th2 
lymphocyte cytokine secretion towards Th1; the modulation of reactive oxygen intermediates (ROI) 
production by neutrophils was also observed. BioMarine had no effect on CD4
+CD25
+ regulatory 
lymphocytes. This study showed no side effects proving that BioMarine is a safe, effective and an 
innate immunity supporting agent. This compound can be effectively used in people with disturbed 
immune system as harmless and effective agent normalizing the immune misbalance. 
Le Blanc et al. [38] studied if Et-16-OCH3 and 1-0-hexadecyl-sn-glycerol (chimyl alcohol) 
possessed the ability to induce functional responses in platelets and chemiluminescence in neutrophils 
and whether they could modify the response induced by PAF. Et-16-OCH3 (1–100 µM) induced 
platelet aggregation but CA did not. Et-16-OCH3 induced platelet aggregation was abolished by 
pretreatment with the PAF receptor antagonist WEB 2086; CA had no effect on platelet aggregation 
induced by PAF, pretreatment with Et-16-OCH3 (0.1 PM or higher) significantly inhibited platelet 
aggregation induced by PAF, but it had no effect on aggregation caused by ADP, thrombin or PMA; a 
receptor binding study using radiolabelled [
3H]WEB 2086 showed that Et-16-OCH3 exerts its actions 
through interaction with the PAF receptor; Et-16-OCH3 inhibited neutrophil chemiluminescence Mar. Drugs 2010, 8  
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responses induced by PAF but not the reactions to PMA or a formyl peptide and 1 µM Et-16-OCH3 
induced a rise in the [Ca
2+]i in platelets equal to that induced by PAF and it also had a calcium 
ionophore-like effect at 100 µM.  
3.2. AKG and cancer 
In an unpublished paper [39] Hajimoradi et al. investigated SLO activity as an immunomodulator. 
They used peritoneal macrophages from female inbred BALB/c mice, aged 8 to 10 weeks, to 
determine the in vitro effect of 100% pure natural arctic SLO, extracted from the Greenland Shark 
Somniosus microcephalus and observed that, with the increase of SLO concentration, nitric oxide 
(NO) production of macrophages increased with no multiplication of cells thus supporting the use of 
SLO as an adjunct therapy in the treatment of neoplastic disorders and as an immune booster in 
infectious diseases. 
Apte et al. [40] described the preparation of pure l-O-hexadecyl-2-palmitoyl-sn-glycero-3-phospho-
(N-palmitoyl) ethanolamine (Figure 3) as well as of the corresponding 1-O-tetradecyl-, 1-O-octadecyl-, 
and 1-O[(Z)-9’-octadecenyl]-derivatives, each of which exhibits a strong antitumor effect in cultured 
neoplastic cells and in mice bearing MC 11 sarcomas. 
Figure 3. Preparation of l-hexadecyl-2-palmitoyl-sn-glycero-3-phospho-(N-palmitoyl)- 
ethanolamine by incubating photomixotrophic cell suspension cultures of rape (B. napus) 
with  rac-1(3)-0-hexadecylglycerol followed by enzymatic and chemical reactions   
(C16H33 = hexadecyl; C15H31CO = palmitoyl; R’CO = acy1). Reprinted from “Biologically 
active ether lipids. Biotransformation of rac-1(3)-O-alkylglycerols in cell suspension cultures 
of rape and semisynthesis of 1-O-alkyl-2-palmitoyl-sn-glycero-3-phospho-(N-palmitoyl) 
ethanolamines, potent antitumor agents” [40], with permission from Elsevier.  
 
Pedrono et al. [41] observed that orally AKG, administered to mice affected by Lewis lung carcinoma 
tumors, reduced metastasis dissemination by 64 ± 8%, whereas SLO effect was 30 ± 9% below 
control. Purified AKG also decreased significantly plasmalogen content in tumors, whereas SLO had 
no such effect. A 5-day treatment with AKG curtailed the presence in tumors of von Willebrand factor, 
a marker of endothelial cells suggesting an anti-angiogenic effect of AKG. This study shows that AKG 
decrease the growth, vascularization, and dissemination of carcinoma tumors in mice.  
Skopinska-Rozewska et al. [42] tested SLO and fish liver oil together with arctic birch ashes in 
Balb/c mice after transplantation of syngeneic L-1 sarcoma observing that both the substances tested, Mar. Drugs 2010, 8  
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alone or in combination, can significantly diminish cutaneous angiogenesis induced by tumor cells and 
tumor growth. 
Hajimoradi et al. [43] assessed the anti-cancer effect of SLO [capsules contain 100% pure natural 
arctic SLO (350 mg/capsule), extracted from the liver of 101 Greenland sharks 
(Somniosus microcephalus). natural vitamin A, D and E (minor amount), AKG (35 mg/capsule) and  
ω-3 PUFA (42 mg/capsule)]. The injection (on 35 mice) of various concentrations of SLO (50, 10, 5, 
2.5 and 0.1 mg/kg/day) indicated that SLO, at the doses of 50 and 10 mg/kg/day, had maximum 
enhancing effect on the delayed-type hypersensitivity (DTH) response after 48 hours; the percentage 
of CD8
+ lymphocytes increased in the mice injected with SLO. SLO (10 mg/kg/day) injected 
intraperitoneally showed a decrease in the rate of tumor growth, but it was not statistically significant. 
After injecting 25 mice with SLO to evaluate the cytokine pattern in the tumor-bearing animals, a 
significant increase in IFN-gamma production was observed. These results underline that SLO may be 
administered for prophylaxis and treatment of disease in immunocompromised patients. 
Wang  et al. [44] investigated whether a methoxy-substituted alkylglycerol-1-O-(2-methoxy) 
hexadecyl glycerol (MHG) might promote a more benign or differentiated phenotype in three human 
colon cancer cell lines with different phenotypic properties (the moderately differentiated and growth 
factor responsive Moser, the growth factor unresponsive and malignant HT29, and the poorly 
differentiated and growth factor unresponsive HCT116). MHG inhibited the growth of all the three 
types of cells to a similar degree; 80% inhibition of cell growth was observed at 25 mM concentration; 
upon increasing the concentration of MHG no further increase in growth inhibition was observed; 
MHG upregulated the production of Carcino-Embryonales Antigen (CEA) in all the three cell lines; 
the Moser cells produced CEA in the amount of 5 ng/10
6 cells. An increase in CEA production was 
observed when the cells were treated with either 10, 25, or 50 mM MHG. Treatment with 50 mM 
MHG upregulated CEA production to above 8 ng/10
6 cells; 6) the HT29 cells produced slightly less 
CEA (4 ng/10
6 cells) than the Moser cells and responded to all concentrations of MHG tested by 
increasing CEA production. Maximal CEA induction (8 ng/10
6 cells) was observed when the cells 
were treated with 25 µM MHG; HCT116 cells produced the least amount of CEA (1–2 ng/10
6 cells). 
Treatment of these cells with 25 µM MHG nevertheless upmodulated CEA production (3–4 ng/10
6 cells); 
the treatment of the HT29 cells with MHG upregulated fibronectin production in a dose-dependent 
manner; the upregulation of fibronectin production was not observed in the Moser and HCT116 cells; 
the HCT116 cells were found to be the most aggressive, while the HT29 cells were intermediately 
aggressive and the Moser cells the least aggressive in terms of anchorage-independent growth and 
cellular invasion; MHG-treated cells showed a reduced propensity to grow in soft agarose in all three 
cell lines. A similar level of inhibition (36–37%) was observed for all cell lines when treated with 
25 µM MHG, and a slightly higher level of inhibition (59%) was achieved for the HCT116 cells when 
treated with 50 µM MHG in comparison with the Moser (49%) and HT29 (44%) cells; MHG-treated 
cells showed a reduced ability to invade a matrigel matrix. The Moser cells did not respond to 
treatment with 25 µM MHG, while a slight reduction in cellular invasion was observed for the HT29 
and HCT116 cells. Treatment of these cell lines with 50 µM MHG reduced the invasive capability of 
the HCT116, HT29 and Moser cells by 47, 35 and 19% respectively. This study shows that MHG is 
biologically active and is able to promote a more benign or differentiated phenotype in these colon 
cancer cells. Mar. Drugs 2010, 8  
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Krotkiewski et al. [45], using the plating efficiency method, assessed the effect of AKG on the 
plating efficiency of human ovarian carcinoma (OVP-10), mammary carcinoma (MCF-7), and prostate 
cancer (DU-145, PC-3 and PCa-2b) cell lines. The cells were exposed to Ecomer® SLO containing 
20% AKG and 3% methoxyderivates in a dose of 0.1 mg/mL, up to a concentration corresponding to 
LD-50. The prostate cells from DU-145, PC-3 and PCa-2B showed a dramatic reduction in the colony 
number even after relatively small doses of 0.5 and 0.1 mg/mL medium; flow cytometry showed an 
increased percentage of apoptotic cells of ovarian and prostate carcinoma, while mammary carcinoma 
cells showed predominantly necrotic cells after exposure to Ecomer®. 
This study shows a clear apoptosis/necrosis-inducing effect of Ecomer in three different cell lines of 
human prostate cancer, and in human mammary carcinoma cells line but no such effect has been 
observed in the human ovarian carcinoma cells. 
Pedrono  et al. [46] studied the effects of AKG (from Centrophorus squamosus;  composition:  
14:0 = 0.7%, 16:0 = 9.1%, 16:1n-7 = 12.5%, 18:1n-9 = 68.1%, 18:1n-7 = 4.8% and other minor 
species (<1%) = 4.8%) on the proliferation of basic Fibroblast Growth Factor (bFGF) stimulated 
endothelial cells. AKG were metabolized into alkyl-glycerophosphocholine and   
alkyl-glycerophosphoinositol, two ether analogues of phospholipids potentially involved in cell 
signalling; AKG were metabolized into several lipids that could influence signal transduction, namely 
alkyl-PA, alkyl-lysoPA and alkyl-acyl-Gro; AKG influenced endothelial cell growth, without any 
cytotoxic effects, and decreased the cell proliferation in a concentration and a time-dependent manner; 
they also reduced the stimulating effect of bFGF and the effects of 0.5, and 5 ng/mL bFGF on growth 
were completely suppressed after 72 h-treatment by 50 microM AKG. This study shows that bFGF 
greatly increases (+56% ± 15) the production of 1-O-alkyl-2-acyl-sn-glycerophosphate in AKG-treated 
endothelial cells, suggesting that the observed effects of AKG could be mediated through 
Phospholipase D activation. This may lead to new therapeutic perspectives.  
Rait et al. [47] showed that anti-ras 3’-end conjugates of minimally phosphorothioate-protected 
oligonucleotides with 1-O-hexadecylglycerol (PPS-C16 ODN) retained the high sequence-specificity 
of PPS ODNs and provided maximal inhibition of Ras p21 synthesis with minimal toxicity even 
without the use of a cellular uptake enhancer. Moreover, treatment of T24, a radiation-resistant human 
tumor cell line that carries a mutant ras gene with anti-ras PPS-C16 ODN, results in a reduction in the 
radiation resistance of the cells in vitro. This study also demonstrated that the growth of RS504   
(a human c-Ha-ras transformed NIH/3T3 cell line) mouse tumors is significantly inhibited by the 
combination of intratumoral injection of anti-ras PPS-C16 ODN and radiation treatment. These 
findings indicate the potential of the combination of antisense and conventional radiation therapy as a 
highly effective cancer treatment modality. 
Reynolds et al. [48] observed that both the human prostate cancer LnCap and DU145 cell lines 
responded to the antiproliferative effect of MHG in a similar manner. In this study MHG inhibited cell 
growth with equal potency in these cell lines with an IC-50 value of 93 µM for LnCap, and 97 µM for 
DU145 while the IC-50 values for phenylbutyrate were 1.3 mM and 7.3 mM, respectively, for LnCap 
and DU145 cells. Compared to the DU145 cells the LnCap cells are at least five times more sensitive 
to the antiproliferative effect of PB, probably due to the differences in the biological phenotype of the 
two cell lines. LnCap cells showed to have a greater propensity to grow in soft agarose than the 
DU145 cells (2,500 vs. 1,500 colonies) and both MHG and PB (IC-50 concentrations) inhibited the Mar. Drugs 2010, 8  
 
 
2280
growth of these cells in soft agarose. As much as over 50% inhibition was achieved for both LnCap 
and DU145 cells by PB and a lesser degree of inhibition was observed with MHG. MHG- and   
PB-treated cells showed a reduced ability to invade a matrigel matrix. Both the LnCap and DU145 
cells invaded the matrigel to a similar extent. Invasion by PB-treated LnCap and DU145 cells was 
reduced, respectively, by approximating to 41 and 30% when compared to untreated control cells. 
Invasion of MHG-treated LnCap and DU145 cells was reduced, respectively, of about 25 and 9%. This 
study showed that MHG in µM concentrations also inhibits cellular proliferation,   
anchorage-independent growth and cellular invasion in the human prostate LnCap and DU145 cells. 
At equivalent IC-50 concentrations it was found that PB is more potent than MHG in inhibiting 
anchorage-independent growth and cellular invasion. However both MHG and PB inhibited the 
malignant properties of these prostate cancer cells but the concentrations required to achieve similar 
inhibitory effect were significantly different for these two agents. 
According to previously described studies, the anticancer effect of AKG might be due to the 
property of activating macrophages, and increasing the cytokines such as IL-12 and IFN-gamma 
production. The recruitment and activation of macrophages, in fact, are acknowledged to be 
fundamental in the primary antitumor defence [49] while IFN-gamma, a T-cell derived lymphokine, 
inhibits a wide number of malignant cells, either directly counteracting cancer cells growth or through 
its immunomodulatory properties [50]. 
IL-12 induces the secretion of IFN-gamma from naive and activated T and NK cells, enhances the 
cytotoxic activity of NK cells, cytotoxic T lymphocytes, lymphokine activated killer cells and 
increases the proliferation of preactivated T cells and NK cells; the IL-12 ability to induce 
differentiation of Th1 cells, and to produce cell-mediated immunity enhancing cytokines, underlines 
how this cytokine plays a key role in promoting host defence and protection against cancer [51,52].  
Another possible scenario, explaining AKG antitumoral activity, could be found in the 
accumulation of O-alkyl groups in tumoral cells which are not able to face the abnormal distribution of 
these glyceryl ether lipids [53] that is due to a low or absent expression of O-alkyl monooxygenase 
enzyme activity with a subsequent accumulation of lipid ethers in the tissue leading to cell death [54]. 
3.3. Alkylglycerols and blood brain barrier 
The discovery of the blood brain barrier (BBB) can be attributed to the researcher Edwin Goldman 
who, in 1913, injected a dye directly into the brain, and realized that the dye failed to spread, 
suggesting that some sort of barrier was keeping it in. The BBB represents a major obstacle to the 
delivery of drugs to the central nervous system (CNS). The BBB consists of several barriers in 
parallel, with the two that are best described being the vascular BBB, consisting primarily of the 
capillary bed, and the blood-cerebrospinal fluid barrier, consisting primarily of the choroid plexus 
[55]. At both sites, the BBB is formed by a monolayer of cells that are cemented together by tight 
junctions and have other mechanisms that control or retard leakage of plasma into the CNS. The BBB 
accomplishes several roles: (1) blocking circulating substances from entering the CNS; (2) it facilitates 
and regulates the entry of many substances that are critical to the CNS function; (3) it secretes 
substances into the blood and the CNS. So it is able to influence the homeostatic, nutritive, and Mar. Drugs 2010, 8  
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immune environments of the CNS and it regulates the exchange of informational molecules between 
the CNS and blood [56].  
Erdlenbruch et al. [57] investigated the spatial distribution of intracarotid fluorescein sodium and 
intravenous lissamine-rhodamine B200 (RB 200) albumin in the brain of normal and C6 glioma-bearing 
rats (Male Wistar rats and male nude mice) after intracarotid co-administration of 1-O-pentylglycerol. 
The differential permeability of the BBB in the absence and presence of 200 mM 1-O-pentylglycerol 
was investigated in tumor-free rats (n = 19) and in rats bearing C6 gliomas (n = 12) using small and 
large fluorescence markers. The delivery of methotrexate (MTX) to the brain of tumor-free nude mice 
was evaluated in the absence and presence of 1-O-pentylglycerol (n = 12). In order to elucidate the 
mechanisms involved in the AKG-mediated BBB opening, intraluminal accumulation of fluorescein 
isothiocyanate (FITC) Dextran 40,000 was studied in freshly isolated rat brain capillaries using 
confocal microscopy during incubation with different AKG. Furthermore, 1-O-pentylglycerol-induced 
increase in delivery of MTX to the brain was evaluated in nude mice. Three microscopic evaluations 
showed a marked 1-O-pentylglycerol-induced extravasation of fluorescein and RB 200-albumin in the 
ipsilateral normal brain. In glioma-bearing rats, increased tissue fluorescence was found in both tumor 
tissue and brain surrounding tumor. Confocal microscopy revealed a time- and concentration-dependent 
accumulation of FITC–Dextran 40,000 within the lumina of isolated rat brain capillaries during 
incubation with 1-O-pentylglycerol and 2-O-hexyldiglycerol, indicating enhanced paracellular transfer 
via tight junctions. Intracarotid coadministration of MTX and 1-O-pentylglycerol (200 mM) in nude 
mice resulted in a significant increase in MTX concentrations in the ipsilateral brain as compared to 
controls without 1-O-pentylglycerol. In this study a strong increase in delivery of fluorescence markers 
of different molecular weight to both normal brain and brain tumors was demonstrated in rats by 
intracarotid coadministration of 1-O-pentylglycerol; an increased drug transfer across the BBB was 
also observed after intracarotid 1-O-pentylglycerol in nude mice. The permeabilizing effect of the 
AKG is mediated at least in part by enhanced permeability of the tight junctions and the ability of  
1-O-pentylglycerol to increase the delivery of small and large compounds to normal brain and brain 
tumors is also mediated at least in part by enhanced permeability of tight junctions. 
The same group [58] analyzed the transfer of MTX across the BBB in normal male Wistar rats to 
elucidate the effectiveness and structure activity relations of the most promising pentyl- and 
hexylglycerol derivatives. The effects were compared with BBB disruption using hypertonic mannitol 
or intracarotid infusion of bradykinin. Toxicity of the AKG has been studied in long-term experiments. 
The authors observed that: (1) apart from 1-O-pentyldiglycerol, all AKG induced a   
concentration-dependent increase in MTX delivery to the brain varying from 1.1 to more than 300-fold 
compared to intra-arterial MTX alone; (2) enhanced barrier permeability rapidly approached baseline 
values within 5 and 120 min at the latest; (3) mannitol 1.4 M resulted in very high MTX levels in the 
brain as observed using the highest concentrations of AKG; (4) intracarotid infusion of bradykinin had 
only a minor effect on the BBB; (5) using 1-O-pentylglycerol or 2-O-hexyldiglycerol, both cell culture 
experiments and long-term in vivo analyses including clinical, laboratory and histopathological 
evaluations revealed no signs of toxicity. 
In summary, intracarotid short-chain AKG constitute a very effective and low toxic strategy for 
transient opening of the BBB to overcome the limited access of cytotoxic drugs to the brain. The 
Authors concluded that short-chain AKG show to increase the transfer of MTX to the brain and Mar. Drugs 2010, 8  
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several instruments have been described to control the AKG mediated increase in barrier permeability. 
In vitro and in vivo assessment reveal that this new concept of BBB opening is associated with no 
toxic effects at therapeutic levels. Therefore intracarotid AKG represent a new therapeutic procedure 
to overcome the limited access of therapeutic agents to the CNS.  
Erdlenbruch et al. [59] investigated a method to chemically open the BBB using intraarterial (i.a.) 
administration of AKG to increase the transfer of erucylphosphocholine (ErPC), a new derivative of 
the alkylphosphocholine (APC) family, into the brain. In contrast to hexadecylphosphocholine, the 
prototypical APC, ErPC can be administered intravenously without causing hemolysis. ErPC possesses 
a cell membrane-mediated mechanisms of action which is thought to be responsible for its ability to 
overcome the chemoresistance against standard anticancer agents frequently observed in high-grade 
gliomas. ErPC was administered to C6 glioma-bearing rats (Wistar rats weighing between 230 and 
305  g which had had free access to a standard diet (Altromin) and tap-water during the whole 
experimental period) either as a single intracarotid bolus injection in the presence or absence of   
1-O-pentylglycerol (300 mM) or as an intracarotid infusion in conjunction with bradykinin. Brain 
tissue concentrations were analyzed and compared to values obtained after intravenous ErPC treatment 
over 14 and 30 days (cumulative ErPC doses of 210 and 350 mg/kg, respectively. Increasing doses 
from 10 to 40 mg/kg, both single intravenous injection (i.v.) and single intracarotid bolus injection of 
ErPC, resulted in brain concentrations under the detection limit of 12 nmol/mg. In the first group 
receiving repeated i.v. ErPC injections (constant dose regimen; 25 mg/kg every 48 hours over 30 days; 
cumulative dose 350 mg/kg), an ErPC accumulation was found in the brain with tissue concentrations 
averaging 152 ± 53 pmol/mg, which exceeded serum levels by about 1.7-fold. Tissue levels of ErPC in 
liver and kidney were higher and those of fat tissue lower than the CNS levels. This study showed that 
ErPC treatment was well tolerated by the animals, the clinical and histological examinations showed 
no signs of ErPC-induced toxicity and the assessment of laboratory parameters revealed no changes 
during ErPC treatment. In the second group receiving i.v. ErPC treatment (saturation regimen), a rapid 
and more pronounced drug accumulation was achieved in both tumor tissue and surrounding tumor-free 
brain. ErPC concentrations averaged 264 pmol/mg in the tumor and 244 pmol/mg in the remaining 
tumor-free brain. Thus, even though the cumulative ErPC dose was significantly lower using the 
saturation regimen (210 mg/kg compared to 350 mg/kg given in the constant i.v. ErPC group), a 
significantly higher ErPC transfer into the CNS was achieved (P < 0.05). The higher initial ErPC doses 
were associated with attenuated weight gain or stagnant body weight, a clinical sign of ErPC-induced 
toxicity. However, laboratory and morphological examinations revealed no other signs of toxicity. The 
single i.a. ErPC injection in the presence of 1-O-pentylglycerol resulted in very high ErPC 
concentrations in brain tumor tissue. Compared to control animals receiving intra arterial ErPC 
without pentylglycerol (aqueous and ethanolic ErPC groups) and with those receiving intracarotid 
bradykinin, a marked increase in drug delivery to the brain tumor and to the ipsilateral and 
contralateral tumor-free brain was achieved. The increased access of ErPC to the brain, after 
coinjection with pentylglycerol, was also associated with significantly lower plasma levels of ErPC. 
The pentylglycerol-mediated BBB opening appeared to be more pronounced in the tumor tissue, as 
evidenced by the concentration difference between tumor (289 pmol/mg) and surrounding brain tissue 
(ipsilateral, 163 pmol/mg). Moreover this study reports that intra arterial bradykinin was not followed 
by an increase in ErPC concentrations in either tumor tissue or surrounding tumor-free brain. Mar. Drugs 2010, 8  
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Using ethanolic ErPC, there were higher ErPC concentrations in all brain regions than after the use 
of aqueous ErPC). Thus, ethanol itself induced an increase in BBB permeability and the ethanolic 
ErPC solution was therefore not suitable as a control to assess the pentylglycerol-associated effects at 
the BBB. 
In summary, pentylglycerol-induced BBB opening dramatically increase the tissue concentrations 
of ErPC in the tumor and surrounding brain after i.a. injection; intracarotid bradykinin is ineffective; 
the ErPC levels measured in the CNS also exceed those obtained after long-term i.v. treatment; in the 
future AKG may represent a novel instrument to increase delivery of chemotherapeutic agents to brain 
tumors but also to more distant regions of the brain containing infiltrating and migrating cells that 
might be responsible for tumor recurrence; the selectiveness of the effect in favour of the tumor tissue 
reduces the potential for toxicity in the normal brain; intra arterial administration of ErPC in the 
presence of AKG is a promising new concept for brain tumor chemotherapy. 
Erdlenbruch et al. [60] investigated the enhancement of the BBB permeability by i.a. administration 
of AKG in tumor-free and C6 astroglioma bearing rats. The antineoplastic agents cisplatin and MTX 
and the antibiotics vancomycin and gentamicin were selectively injected into the right internal carotid 
artery in the absence and presence of various alkylmono-, alkyldi-, and alkyltriglycerols. I.a. injection 
of CDDP, MTX, gentamicin, or vancomycin into the right internal carotid artery of rats in the absence 
of AKG resulted in low tissue concentrations of each drug with no regional differences between the 
right hemisphere, the left hemisphere and the cerebellum. Simultaneous administration with various 
AKG analogues showed an accumulation of the drugs in the brain, predominantly in the ipsilateral 
right hemisphere; using 1-O-pentylglycerol (0.3 M) the tissue concentrations in the ipsilateral 
hemisphere were increased 230-fold (MTX), 125-fold (CDDP), 15-fold (vancomycin) and 12-fold 
(gentamicin) compared to the injection in the absence of AKG (1E-H, n = 6 in each group); AKG 
effect on the blood-brain barrier was concentration dependent and increased with the chain length of 
the alkyl group; Heptyl- and octyl derivatives were highly potent even at low doses, resulting in high 
concentrations of the coinjected drugs in the ipsilateral hemisphere and also, to a lesser extent, in the 
contralateral hemisphere and cerebellum; enhancement of drug delivery to the brain was weakened by 
the high polarity of the diglycerol and, in particular, the triglycerol analogues; the administration of 
CDDP together with 1-O-butyl- or 1-O-pentylglycerol was responsible for a significant accumulation 
of CDDP in the right hemisphere, while the shorter 1-Opropyl-and the spheroid 1-O-tert-butylglycerol 
were ineffective; the 2-O-alkyl-isomers were less effective than the respective 1-O-alkyl-isomers 
probably due to a decrease in lipophilia of the molecules; separating the injection of AKG and MTX or 
CDDP by a time interval of 3 or 15 min led to an extensive attenuation or a complete loss (CDDP) of 
the enhanced barrier permeability but the effect of the AKG at the blood-brain barrier was reversible 
within a few minutes; hematological and serum analyses (sodium, potassium, calcium, glucose, total 
protein, aminotransferases, lactate dehydrogenase, bilirubin, and creatinine) revealed no acute toxic 
side effects of the monoglycerol analogues up to 0.3 M (hexylmonoglycerol was only injected up to 
0.1 M); the diglycerol derivatives caused hemolysis at concentrations exceeding 0.1 M.   
2-O-Heptyl-triglycerol and 2-O-octyltriglycerol were hemolytic exceeding concentrations of 0.075 and 
0.05 M, respectively; coadministration of 1-O-pentylglycerol with MTX at the blood-tumor barrier to 
C6 rat astroglioma bearing rats showed that in the presence of 1-O-pentylglycerol (0.3 M) the 
concentrations of MTX were increased 18-fold in the tumor, 28-fold in the surrounding brain, 18-fold Mar. Drugs 2010, 8  
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in the contralateral brain, and 19-fold in the cerebellum compared with MTX controls in the absence 
of pentylglycerol.  
3.4. Alkylglycerols and plasmalogens 
1-(1’-Alkenyl)-2-acyl glycerophospholipids and plasmalogens are the two types of phospholipids 
that may occur in biological tissue. Plasmalogens are characterized by a Z-double bond in the   
1-alkenyl moiety next to the ether linkage. The exact percentage of plasmalogens varies from organ to 
organ as well as from species to species. In the heart over 25% of the phospholipids can be 
plasmalogens but they are present also in the liver, retina, brain and kidneys [61]. Plasmalogens were 
discovered in 1924 by Feulgen, whose studies leaded to the isolation in 1939 of a crystalline 
phospholipid-containing higher fatty aldehyde, glycerol phosphorus, and ethanolamine. Their 
proposed acetal structure has since served as a prototype of this class of lipids (Figure 4).  
Figure 4. Plasmalogen acetal structure proposed by Feulgen in 1939 [61]. 
 
Myocardial sarcolemmal phospholipids are comprised predominantly of plasmalogen molecular 
species, and a growing body of evidence indicates that plasmalogen phospholipids may play a role in 
the pathophysiology of some heart diseases. Thus plasmalogens are believed to be involved in the 
sarcolemmal dysfunction associated with myocardial ischemia and reperfusion. It has been speculated 
that the distribution of plasmalogens in the heart might affect the bilayer stability, which may be 
instrumental in sarcolemmal destruction during ischemia and reperfusion. Membrane phospholipids 
are known to play a key role in myocardial ischemia reperfusion injury. Reperfusion of ischemic 
myocardium is associated with the loss of membrane phospholipids with the accumulation of 
lysophosphoglycerides and free fatty acids, especially arachidonic acid (AA). Mammalian hearts 
contain two types of phospholipids, diacyl and ether glycerolipids, also known as plasmalogens. A loss 
of plasmalogens occur in the pathogenesis of ischemic heart disease. Alkyl glycerols such as chimyl 
alcohol, can serve as a precursor for the formation of plasmalogens in the microsomes. 
Maulik et al. [62] designed a study to examine whether supplementation of the heart with chimyl 
alcohol prior to ischemia could reduce the ischemia reperfusion injury. The study was performed in 
Sprague-Dawley rats weighing approximately 300 g. Their hearts were quickly removed and perfused 
by the Langendorff technique. The animals were divided into two groups: (1) the experimental group 
which received 50 pM chimyl alcohol prior to ischemia; (2) the control group which received 50 pM 
of saline. After 15 min of perfusion with or without the chirnyl alcohol, the heart was arrested at 
normothermia terminating the coronary flow. Coronary flow was significantly higher in the 
postischemic chimyl alcohol-treated heart as compared to the matched control; left ventricular Mar. Drugs 2010, 8  
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developed pressure, during the reperfusion phase was also significantly better in the experimental 
group (9 ± 1 versus 13 ± 2 mm Hg); creatine kinase (CK) release from the postischemic heart was 
increased significantly from both the control and chimyl alcohol groups, but the amount of CK release 
was much lower in the treated group as compared to the control group (60 ± 10 versus 106 ± 9 IUII) 
after 30 min of reperfusion; the amount of malondialdehyde (MDA) in the postischemic heart was 
increased steadily in both groups, but the increase was significantly lower in the chimyl alcohol group 
(0.166 ± 0.008 versus 0.08 ± 0.002 nmol/mL); the peroxisomal catalase was significantly lowered in 
the postischemic heart (11.26 ± 0.8 versus 15.6 ± 0.35 nmol/min/mg protein); treatment with chimyl 
alcohol restored the catalase activity to the pre-ischemic baseline level (16.24 ± 0.67 nmol/min/mg 
protein). The authors concluded that reperfusion of ischemic myocardium may lead to the peroxisomal 
disorder. Chimyl alcohol can protect the ischemic heart from reperfusion injury probably by enhancing 
the plasmalogen synthesis. Moreover the MDA significantly lower increase in the postischemic heart 
in the chimyl alcohol treated group suggests that this AKG is able to reduce oxidative stress. 
Schrakamp et al. [63] studied de novo plasmalogen biosynthesis measuring the incorporation of  
[1-
14C]hexadecanol into the alkenyl side chain of ethanolamine and choline plasmalogens of cultured 
skin fibroblasts from patients with different peroxisomal or related diseases, from heterozygotes for 
Zellweger syndrome and infantile Refsum disease, and from controls. After [1-
14C]hexadecanol 
incorporation plasmalogen biosynthesis was normal in fibroblasts from patients with X-linked 
drenoleukodystrophy, adrenomyeloneuropathy, Refsum disease, and X-linked chondrodysplasia 
punctata. About 45% and about 4.5% of total phospholipid radioactivity is present in these cases in the 
alkenyl chains of ethanolamine and choline plasmalogens, respectively; plasmalogen biosynthesis was 
found to be strongly impaired in fibroblasts of patients with neonatal adrenoleukodystrophy, infantile 
Refsum disease, Zellweger syndrome, and rhizomelic chondrodysplasia punctata; rhizomelic 
chondrodysplasia punctata is most severely deficient in plasmalogen biosynthesis (2.4 and 0.5% of 
radioactivity in alkenyl chains of ethanolamine and choline plasmalogens, respectively), followed by 
Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease, in this order. 
Heterozygotes for Zellweger syndrome and infantile Refsum disease behaved like controls with 
respect to their plasmalogen biosynthetic capacity; no accumulation of alkylphospholipids in 
fibroblasts was found for any disease suggesting that the plasmalogen deficiency, reported before, is 
caused by impaired glycerol-ether bond formation in all these disorders; incorporation of   
l-O-[9,10-
3H2]octadecylglycerol into ethanolamine and choline plasmalogens of fibroblasts of 
different peroxisomal diseases substantiated that the deficiency of plasmalogen biosynthesis in 
rhizomelic chondrodysplasia punctata, neonatal adrenoleukodystrophy, and infantile Refsum disease is 
at or before the introduction of the ether bond by peroxisomal enzymes.  
Zoeller et al. [64] showed that supplementation of cultured human pulmonary arterial endothelial 
cells (PAEC) with sn-1-O-hexadecylglycerol (HG) resulted in an approximately twofold increase in 
cellular levels of plasmalogens. Exposure of unsupplemented human PAEC to hypoxia   
(pO2 ~ 20–25 mmHg) caused an increase in cellular reactive oxygen species (ROS) over a period of 
five days with a coincident decrease in viability. In contrast, HG supplemented cells survived for at 
least two weeks under these conditions with no evidence of increased ROS. Hypoxia resulted in a 
selective increase in the turnover of the plasmalogen plasmenylethanolamine. Human PAEC, with 
elevated plasmalogen levels, were also more resistant to H2O2, hyperoxia, and the superoxide Mar. Drugs 2010, 8  
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generator plumbagin. This protection was seemingly specific to cellular stresses in which significant 
ROS were generated because the sensitivity to lethal heat shock or glucose deprivation was not altered 
in HG-treated human PAEC. HG, by itself, was not sufficient for protection; HG supplementation of 
bovine PAEC had no effect upon plasmalogen levels and did not rescue these cells from the cytotoxic 
effects of hypoxia. This study shows that the plasmalogen content of human PAEC can be enhanced. 
This is associated with an increased resistance to hypoxia as well as to the specific ROS or ROS 
generators. The use of HG to increase plasmalogen can have important implications for therapeutic use 
against hypoxia. 
3.5. Alkylglycerols and radiation therapy 
Hichami  et al. [65] designed a study using a 
3H-labelled or unlabelled natural AKG mixture 
[prominent alkyl chains were C18:1(9) (54–65%), C16:1(7) (5–15.5%), and C16:0 (5–10%)] to better 
understand the protection mechanism which is hypnotized to be mediated by AKG incorporation into 
pools of PAF precursor and subsequent modification of PAF biosynthesis. The authors investigated the 
incorporation of AKG into phospholipids of human leukemic monocyte-like THP-1 cells. Incubation 
of cells for 24 hours with [
3H]AKG (10 µM) resulted in their incorporation into   
1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine and into 1-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine 
with a total yield of 6.5%. The incorporation induced production of   
1-O-[
3H]alkyl-2-acetyl-sn-glycero-3-phosphocholine ([
3H]PAF), which was increased after stimulation 
by the calcium ionophore A23187. HPLC analysis of the [
3H]PAF molecular species indicated that the 
three major [
3H]AKG were used for [
3H]PAF synthesis in ratios similar to that of the mixture. Total 
production of biologically active PAF, as measured by the platelet-aggregation bioassay, was also 
increased by AKG incorporation in resting (120%) and in A23187-stimulated (159%) THP-1 cells. 
HPLC analysis of the [
3H]PAF produced in the presence of [
3H]acetate, confirmed that levels of PAF, 
but not of its 1-acyl analog, were increased by AKG incorporation in resting and stimulated cells. 
However, the rise in [
3H]acetyl-PAF, which resulted mainly from C16:0 PAF, was reduced by about 
50% in the presence of the PAF-receptor antagonist SR 27417, providing evidence that stimulation of 
total PAF synthesis was caused by the increase in the precursor pool and autocrine amplification of 
PAF-induced PAF production. Thus, the supplementation of THP-1 cells in culture with naturally 
occurring AKG led to the incorporation of AKG into ether-containing phospholipids which were 
subsequently used for PAF synthesis. Furthermore, AKG incorporation resulted in a significant rise in 
PAF production by THP-1 cells under resting and stimulated conditions. This study highlights that:  
(1) PAF species profile could be altered by the addition of, for example, C18:1 AKG; PAF exerts an 
important role in several pathophysiological situations and the possibility to modulate its synthesis 
could be an important tool to fight these pathologies; (2) Zellweger syndrome, a pathological 
condition, characterized by the absence of ultrastructurally detectable peroxisomes in patients’ tissues 
associated with the absence of ether-lipid synthesis, could be eased by a dietary supplementation 
with AKG. 
Joelsson [66] designed a study to assess whether or not AKG, administered before and during in a 
prophylactic approach or only during in a therapeutic perspective, influence the incidence of injuries 
following radiotherapy for carcinoma of the uterine cervix. The Author used AKG preparation from Mar. Drugs 2010, 8  
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the liver oil of the Greenland shark (concentrate containing 85% free AKG) administered orally in 
capsules containing 0.1 g. The total daily dosage amounted to 0.6 g. The patients with invasive 
carcinoma of the uterine cervix were assigned to one of the following groups: (1) patient receiving 
AKG prophylactically (during 7 days before and during the treatment period as well as for 1-3 months 
after the completion of radiotherapy); (2) patients receiving AKG only during the period of 
radiotherapy plus non-prophylactic administration for 1–3 months thereafter; (3) patients receiving 
radiotherapy solely. In this study the injuries, due to the combination of radiation tissue damage and 
residual and or recurrent tumor growth, were classified as complex injuries (C-injuries) and have been 
considered in addition. The sum of the injuries (R-injuries + C-injuries) was defined as the total 
number of injuries (I-injuries). The injuries were classified as: (1) grade I: injuries producing mild 
subjective symptoms accompanied by minimal objective changes in the mucosa of the organ. These 
injuries were considered as radiation reactions rather than real injuries and had consequently been 
omitted; (2) grade II: injuries which are composed of moderately to severe objective changes, such as 
areas of necrosis, ulcers or moderate stenosis; (3) grade III: bladder and ureter injuries comprising 
fistulas, and rectal and intestinal injuries comprising stenoses to such an extent that colostomy has 
been required; (4) grade IV: rectal and intestinal fistulas. Injuries which appeared within three months 
of treatment had been excluded and those injuries which were not clearly related to the radiation 
treatment or to tumor growth were also omitted. The authors, after the supplemention with AKG, 
observed that: (1) the incidence of total grade II injuries (I-injuries, grade II) was 9% in the 
prophylactic group and 24% in the control group (i.e., a reduction of 60% was observed); (2) the 
incidence of grade II radiation injuries (R-injuries, grade II) was considerably reduced while no effect 
was observed on radiation injuries of grade III and IV; (3) the complex injuries of all grades were 
markedly reduced; (4) in the non-prophylactic group only the radiation injuries were reduced while the 
incidence of the complex injuries remained the same. The Author paid particular attention to the effect 
of AKG on the incidence of fistulas following radiation therapy (bladder injuries of grade III and rectal 
injuries of grade IV together constituted the fistulas). The author reported that: (1) the total number of 
fistulas (I-injuries grade III and IV, bladder and rectum) was considerably lower in the prophylactic 
group than in the control group (6.2% compared with 11.6%); (2) the fistulas, belonging to the 
complex injury group (C-injuries grade III and IV, bladder and rectum), had a low figure of to 2.9% 
compared with 7.3%; (3) the pure radiation fistulas (R-injuries grade III and IV, bladder and rectum) 
but not the fistulas of complex origin were decreased in number in the non-prophylactic group. 
In summary an inhibition of tumor growth and a decrease of the number of both radiation and 
complex injuries was observed when AKG had been administered prior to radiation treatment of 
patients affected by cancer of the uterine cervix. In particular this study highlights that prophylactic 
administration of AKG markedly reduced fistulas proving the potential clinical importance of AKG as 
a complement to conventional radiation therapy in cancer treatment. 
3.6. Antibacterial and antifungal activity of dodecylglycerols 
Lipids, particularly fatty acid esters of polyhydric alcohols, have been widely reported to be 
antimicrobial agents. For a long period the monoglyceride dodecanoylglycerol (monolaurin) was 
known to be the most potent [67–68], but more recently DDG, the corresponsing AKG ether, has Mar. Drugs 2010, 8  
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shown a considerably higher efficacy, probably due to a greater metabolic and chemical stability of 
ether bonds compared to esters.  
DDG has been reported to exert its antibacterial activity by the activation or release of proteases 
which convert the autolytic enzyme autolysin from a latent inactive form to an active state. DDG was 
also found to be able to act by inhibiting the synthesis of the peptidoglycan in bacterial cell walls. 
Moreover its antifungal activity has been proved against several species of Candida and Cryptococcus 
[69]. Here we are going to summarize several clinical trials involving the use of DDG to test its 
antibacterial and antifungal properties.  
Brisette et al. [70] used Streptococcus mutans BHT to study the response to DDG since the ether 
has a profound growth-inhibitory effect without inducing cellular lysis. S. mutans BHT is tolerant to 
penicillin and several other cell wall inhibiting antibiotics and responds to penicillin stimulating lipid 
and lipoteichoic acid synthesis and excretion. Growth-inhibitory concentrations of racemic   
sn-l(3)-dodecylglycerol inhibited the incorporation of [
14C] glycerol into lipids and lipoteichoic acid of 
Streptococcus mutans BHT and altered the per cent composition of the glycerolipids; increases in 
phosphatidic acid and diphosphatidylglycerol (at the expense of phosphatidylglycerol) contributed the 
most to the change in lipid composition. No cellular lysis occured under these conditions; radioactive 
racemic  sn-1(3)-dodecylglycerol is readily taken up by the cell and is metabolized primarily to 
lysophosphatidic acid and phosphatidic acid with smaller amounts converted to phosphatidylglycerol 
and diacylglycerol; the accumulation of phosphatidic acid and the loss of viability responded in 
parallel to different concentration of DDG; an increase in phosphorylcholine cytidylyl-transferase was 
also observed; this increase united to the the increase in phosphatidic acid suggested a possible 
impairment in the synthesis of CDP-diacylglycerol. 
In summary, DDG (10 and 20 µg/mL) is able to inhibit glycerolipid and lipoteichoic acid synthesis 
from glycerol in S. mutans BHT basing on the observation that in cultures pre-equilibrated with 
[
3H]glycerol or [
14C]glycerol, DDG inhibited the incorporation of radioactive label into the 
glycerolipids. In the presence of 217 µM glycerol, DDG in a concentration of 38.4 µM (10 µg/mL) is 
readily taken up, metabolized, and inhibits lipid synthesis at the CDP-diacylglycerol synthetic step. It, 
in fact, inhibits the uptake and incorporation of [
14C]glycerol into lipid. DDG functions as a metabolic 
effector, in fact DDG is an effective antibacterial agent at low concentrations (only a few µg/mL) and 
is strengthened by the present finding that DDG is metabolized, to lyso- and phosphatidic acid 
compounds. Furthermore, the accumulation of phosphatidic acid, both ether-containing and the natural 
difatty ester, suggests that there is a metabolic block at the CDP-diacylglycerol synthetase step. This 
metabolic effect is observed in the absence of any cellular lysis in S. mutans BHT. This, then, is the 
third known mechanism (of possibly many) by which DDG can interfere with normal bacterial 
metabolism. The other two are that it stimulates a proteinase (in S. faecium) which activates an 
autolysin, and it inhibits peptidoglycan synthesis. One or both of these metabolic changes are probably 
triggered by a disturbance induced by DDG to the hydrophobic environment of cellular membrane. A 
final conclusion is that DDG is bactericidal in S. mutans BHT. Substantial decreases of viability 
correlate closely with the accumulation of phosphatidic acid and a decreased energy profile. Moreover 
DDG shows to be able to kill the penicillin-tolerant bacterium, S. mutans BHT, proving to be valuable 
in combating tolerant bacteria where antibiotic tolerance has been correlated with an increased 
lipid content. Mar. Drugs 2010, 8  
 
 
2289
Weber et al. [71] investigated the use of orally administered rac-1-O-[l'-14C]dodecylglycerol in 
mice (female NMRI mice weighing 20–25 g). The substrate was rapidly absorbed in the intestine and 
then incorporated into ether glycerolipids of various organs,and tissues in high proportions; in intestine 
and liver large amounts of rac-l-O-[l'-14C]dodecylglycerol were catabolized by oxidative cleavage of 
the ether bond followed by degradation of the radioactive cleavage product, i.e., lauric acid, to   
water-soluble metabolites that were excreted in the urine at a fast rate; after feeding of a   
rac-1-0-dodecylglycerol-containing diet (1 g rac-1-O-dodecylglycerol/kg body weight × day) given 
over a period of 4 weeks the author did not observe a significantly altered body or organ weights of 
mice; analysis of total lipids revealed that high proportions of the substrate were incorporated into 
ether lipids of all organs and tissues during the feeding period, generally accompanied by a remarkable 
increase in saturated acyl moieties and a concomitant decrease of linoleoyl moieties of total lipids. Yet, 
four weeks after removal of the ruc-1-O-dodecylglycerol-containing diet, the lipids of murine organs 
and tissues showed a close resemblance to those of the control group. The author, based on the 
previously reported results, concluded that rac-l-O-[1'-14C]dodecylglycerol is converted to common 
intermediates of ether lipid metabolism in mammals. In this study two major routes for the metabolism 
were observed: (1) the substrate enters the pathway of ether glycerolipid biosynthesis as a direct 
precursor and (2) rac-1-O-dodecylglycerol as well as ether lipids derived from it, are oxidized by the 
action of an alkyl monooxygenase. Lauric acid thus formed is not esterified into acyl glycerolipids to 
an appreciable amount, but further oxidized to acetate and other water-soluble compounds at a fast 
rate. Only trace amounts of the substrate are excreted in feces. Moreover the author underlined that 
feeding of a rac-1-O-dodecylglycerol-containing diet did not significantly alter body and organ 
weights in mice.  
Haynes et al. [69] tested DDG's bactericidal and antifungal activity against species of Candida and 
Cryptococcus which are the major genera causing fungal infections in AIDS patients. All fungi tested 
were originally isolated from clinical material. From the genus Cryptococcus, the species 
Cryptococcus neoformans (six strains, i.e., ATCC 76484 and five isolates from Temple University 
Hospital [TUH]), Cryptococcus albidus (one strain, a TUH isolate), and Cryptococcus laurentii (one 
strain, a TUH isolate) were assayed. From the genus Candida, the species Candida albicans (one 
strain [ATCC 32354]), Candida tropicalis (two strains, both of which were TUH isolates), and 
Candida parapsilosis (two strains, both of which were TUH isolates) were studied. The authors 
reported that: (1) the AKG ether rac-1-O-dodecylglycerol inhibited the growth of members of two 
genera of yeasts, Candida and Cryptococcus, and was strongly synergistic with amphotericin B; (2) at 
one-half its minimal inhibitory concentration (MIC), DDG decreased the MIC of amphotericin B by as 
much as 80-fold. This high degree of synergism between DDG and amphotericin B was demonstrated 
against a number of species of yeasts including Candida albicans,  Candida tropicalis, 
Candida parapsilosis, Cryptococcus neoformans, Cryptococcus albidus, and Cryptococcus laurentii; 
(3) all fractional inhibitory concentrations, for all strains and species, were calculated to be less than 1, 
and most were less than 0.6, again demonstrating strong synergism; (4) other AKG ethers with alkyl 
chain lengths ranging from 8 to 18 carbon atoms were also found to be synergistic with amphotericin 
B against C. neoformans and C. albicans; (5) electron microscopy experiments showed that 
C. neoformans grown in the presence of DDG had severely abnormal and deformed capsules; (6) DDG 
was observed not to simply act as a detergent. The natural detergent sodium deoxycholate, also present Mar. Drugs 2010, 8  
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in commercial amphotericin B preparations, had no effect at the concentrations of DDG that killed the 
fungi. So did sodium deoxycholate when it was used in combination with Amphotericin B; (7) DDG 
did not interact synergistically with the water-soluble antifungal agent fluconazole emphasizing that 
the lipid-soluble hydrophobic properties of amphotericin B could exert a key role in the synergistic 
interaction between DDG and amphotericin B; (8) AKG ethers could promote synergism with 
amphotericin B potentially increasing the interaction between membrane-bound ergosterol and 
amphotericin B. This study underlines a strong synergistic interaction between DDG and amphotericin 
B in inhibiting the growth of both Candida and Cryptococcus species. They hypotized that DDG may 
act through a mechanism which alters the fluidity of the fungal membrane because it is less 
hydrophobic than the usual membrane glycerolipids. The Authors observed that the concentrations at 
which DDG functioned were too low so that it could work as a surfactant, detergent, or emulsifier, 
which simply dissolved away the lipid-soluble compounds of the membrane resulting in the lysis or 
rupture of the membrane. This consideration leaded the Author to the hypothesis that the fluidity of the 
membrane changes sufficiently to alter the hydrophobic environment which changes the activity of key 
membrane-bound enzymes. When DDG acts synergistically with amphotericin B, it is possible that 
some of the enzymes, whose activities have been altered because of the membrane fluidity changes, 
elicited by DDG, are cell wall synthesizing or cell wall-degrading enzymes. amphotericin B kills fungi 
by binding to the ergosterol in the membrane. The major deterrent to amphotericin B to reach the 
ergosterol in the membrane is the tight framework of the cell wall. Consequently the authors proposed 
that a possible mechanism for the synergy observed between DDG and amphotericin B is that DDG is 
able to act weakening the cell wall because of altered cell wall-synthesizing and/or degrading enzyme 
activity, then amphotericin B would increase access to the membrane ergosterol. The electron 
micrograph studies with C. neoformans seem to support this hypothesis. This study reports interesting 
data which are encouraging for the development of new antifungal therapy. 
Ved et al. [72] treated S. faecium ATCC 9790 with 3.5 pg/mL of DDG observing the production of 
a non-wall entity found in the 25,000× g supernatant cell fraction which activates the autolysin activity 
of S. faecium. The stimulation of the autolysin activity through DDG mimics the activation of the 
autolysin from a latent to an active form through trypsin and other proteolytic enzymes. The Authors 
observed that the stimulation of autolytic activity through DDG can be reversed by specific proteinase 
inhibitors. Moreover DDG also markedly stimulates the proteinase activity endogenous to S. faecium, 
and this stimulation can be reversed by several proteinase inhibitors.  
This study shows that DDG does not act directly on the autolysin of the cell wall of S. faecium, but 
rather through an intermediary of cytosolic (or possibly membrane) origin. Since the autolytic activity 
of S. faecium is known to be converted from an inactive to an active form by proteolytic action, it is 
likely that this intermediary is the proteinase activity endogenous to S. faecium. This proteinase can be 
stimulated by DDG and this stimulation can be reversed by specific proteinase inhibitors which also 
reverse the stimulation of autolysin activity through DDG. In conclusion, a primary antibacterial mode 
of action of DDG is to stimulate the proteinase of S. faecium, which in turn activates autolysin activity 
and prevents bacterial growth.  
Ved et al. [73] designed a study using S. faecium ATCC 9790 as primary test organism to assess the 
effect of DDG on the autolysin activity (0-1,4-N-acetylmuramylhydrolase) of this bacterium. This 
organism has a peptidoglycan hydrolase activity, which catalyzes the cleavage of the p-1,4 linkage Mar. Drugs 2010, 8  
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between N-acetylmuramic acid and N-acetylglucosamine of the peptidoglycan. A latent form of this 
autolysin has been purified to near homogeneity and has demonstrated that it is converted to an active 
form by proteinases. This study showed that: (1) DDG has a minimum inhibitory concentration of 
4 pg/mL compared to 9 pg/mL for 1(3)-dodecanoyl-sn-glycerol (monolaurin-dodecanoylglycerol: the 
fatty acid dodecanoic acid is esterified to glycerol) with S. faecium ATCC 9790 as the test organism; 
(2) the greater potency of DDG can be correlated to its greater retention by the cell; (3) Gram-positive 
bacteria are more susceptible than Gram-negative bacteria to DDG; (4) the antibacterial action of DDG 
is not through the physical dissolution of cell walls, but rather as an enzymatic effector; (5) the 
autolysin activity of whole cells of S. faecium is greatly stimulated by DDG; (6) the stimulation of 
autolytic activity and inhibition of growth respond in parallel to different concentrations of DDG, to 
DDG versus some poorer effector such as monolaurin or a glycerol alkyl ether with a longer or shorter 
fatty alkyl side chain as dodecanol, and to the antagonistic effects of diphosphatidylglycerol. The 
Authors, basing on these results, observed that the greater potency of antibacterial activity of DDG can 
be probably attributed to the fact that ethers are not easily degraded to glycerol and fatty acid as the 
corresponding esters are. They underlined that the conjugated form of fatty acids, that is fatty acyl 
glycerol, is known to be a more potent antimicrobial agent than either fatty acid or glycerol alone 
because the metabolic stability of the ether bond permits the retention of the molecule in a more potent 
form. Moreover they emphasized that the antibacterial activity of the ethers increased progressively 
with an increase in the fatty alkyl chain length up to 12 carbons. However, further 2-carbon increases 
in the chain length caused a decrease in the antibacterial potency of the resulting 1-0-alkylglycerol 
compounds. This could partly be due to the relative hydrophobic and hydrophilic properties of the 
different ethers. A hydrophilic nature is necessary for solubility (increased availability) in the 
suspending medium, and a hydrophobic property facilitates uptake of the compound into the bacterial 
cell thereby allowing its metabolic effects to be exhibited. The glycerol ether of dodecanol compared 
to other fatty alcohols probably represents the best balance between hydrophobic and hydrophilic 
characteristics, and hence it more efficiently brings about the desired antimicrobial effect. In summary: 
(1) DDG exhibits its antibacterial activity at relatively low concentrations; (2) at these low 
concentrations, DDG functions metabolically rather than through a direct physical lytic action;   
(3) DDG stimulates the autolytic activity of S. faecium, and the degree of stimulation always occurs 
under conditions that bring about the same degree of bacterial growth inhibition. Since the proper 
functioning of the autolysins is critical to the wellbeing of the bacterial cell, it is quite possible that the 
stimulation of the autolysin could be a primary, but not necessarily the only mechanism by which 
DDG and related compounds exert their antibacterial activity; (4) DDG does not stimulate the 
autolysin of S. faecium directly (as observed with the segregated cell wall autolysin), but rather 
through an indirect means which requires the involvement of a membrane- or cytosol-associated 
entity. The autolysin of S. faecium is known to be converted from an inactive to an active form 
by proteinases. 
3.7. Other studies involving alkylglycerols 
Twenty-five patients with recurrent aphthous stomatitis (RAS) were enrolled in a study designed by 
Guaranska et al. [74] and received treatment with SLO during a three-month period. The frequency of Mar. Drugs 2010, 8  
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occurrence of RAS decreased from 1.56 before treatment to 0.95 after treatment and the number of 
lesions per month was significantly reduced during the third month of treatment and two months after 
treatment; during two months after treatment four patients had no ulcers and an improvement was 
exhibited in all except three of the remaining patients; a better response of neutrophils to Opsonized 
Zymosan and PMA were seen; the B cell and T CD3/HLA DR+ cell percentage returned to normal 
values; a significantly increased percentage of T cells was observed as compared to the previous 
treatment value; the level of C4 and the hemolytic activity of the complement system decreased after 
treatment and neared the normal values. This study underlines that SLO has a positive 
immunomodulation action and is able to alleviate the course of RAS. AKG ability to amplify the PAF 
biosynthesis in a monocyte cell line, which is known to be produced by mammalian sperm and to be 
an important activator of sperm motility, was used as a starting point to evaluate the effect of in vitro 
treatment of boar spermatozoa with natural 1-O-alkylglycerols (10 mM) on: (1) boar sperm motility; 
(2) production of PAF and its metabolite, lyso-PAF, by spermatozoa; (3) fertility in artificial 
inseminations of breeding sows. A computer-assisted spermatozoa analyzer found that   
1-O-alkylglycerols increased percentage motility as well as velocity parameters after 24 h. These 
effects were partially or totally reversed by the PAF receptor- antagonist SR 27417. After   
[
3H]-1-O-alkylglycerol incubation with boar spermatozoa Cheminade et al. [75] identified   
[
3H]lyso-PAF by high-performance liquid chromatography. Production of PAF and lyso-PAF was 
measured with a biological assay using [
3H]serotonin release from rabbit platelets.  
1-O-alkylglycerols significantly increased lyso-PAF production; 1-O-alkylglycerols had no effect 
on PAF production. The effect of 1-O-alkylglycerols on fertilization was also evaluated in industrial 
breedings: 1-O-alkylglycerol treated or untreated semen dilutions were alternately used for artificial 
inseminations of sows on 12 farms. 1-O-alkylglycerol treatment increased the number of farrows but 
had no effect on the mean size of the litters. In summary, 1-O-alkylglycerol treatment of boar 
spermatozoa in vitro improves their motility and fertility; the use of a PAF-receptor inhibitor is able to 
reverse the effect on motility and the PAF-receptor activation has a key role in the AKG effect 
on motility. 
Zhang et al. [76] designed a study to test the hypercholesterolemic activities of pure squalene and 
SLO in hamsters [five groups (n = 6) of male Golden Syrian hamsters (Mesocricetus auratus, 95 ± 5 g)] 
fed one of five different diets. The diets were: (1) a control diet prepared by mixing the powdered 
ingredients in the following proportions: casein, 242 g; lard, 50 g; starch, 508 g; sucrose, 119 g; 
mineral mix, 40 g; vitamin mix, 20 g; and DL-methionine, 1 g; (2) other four diets prepared by adding 
0.05, 0.1 and 0.5% pure squalene or 0.05% squalene containing SLO into the control diet. All powered 
diets were then mixed with gelatin solution (20 g/L) in a ratio of 200 g diet per liter of solution. Once 
the gelatin had set, the diet was cut into approximately 20 g cubic portions and stored frozen (−20 °C). 
The authors observed that: (1) there were no significant differences in body weight gain except for the 
0.5% squalene supplemented group, which had a final body weight (128 ± 3 g) significantly higher 
than the control (116 ± 6 g), 0.05% squalene-supplemented group (116 ± 7 g), and 0.1%   
squalene-supplemented group (112 ± 8 g). For the daily food intake, no significant difference was 
observed among the control and tested groups; (2) serum total cholesterol concentrations in the 
experimental groups were observed to be generally higher than the control hamsters. When compared 
with the control group, total cholesterol was elevated by 32% in 0.05% squalene group, by 23% in the Mar. Drugs 2010, 8  
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0.10% squalene group, by 35% in the 0.5% squalene group and by 19% in the 0.05% SLO group. The 
similar trend was observed for serum triglycerides. However, only 0.05% and 0.5%   
sualene-supplemented groups had serum total cholesterol concentrations significantly higher than the 
control (P < 0.05). There was no significant increase in the 0.1% squalene-supplemented and 0.05% 
SLO-supplemented groups when compared with the control group. High-density lipoprotein 
cholesterol (HDL-C) was significantly elevated in 0.1% squalene, 0.5% squalene and 0.05% SLO 
groups but not in the 0.05% SQ group as compared with that in the control hamsters. No significant 
differences in serum non HDL-C were observed among the five groups; (3) squalene or SLO feeding 
elevated hepatic cholesterol by 97–133% in the four tested groups compared with the control hamster. 
In contrast, the cholesterol levels in adipose tissue of the four tested groups remained unchanged as 
compared with that in the control except 0.5% squalene-supplemented group. No differences in the 
cholesterol levels of heart were observed among the five groups; (4) the liver squalene concentration 
in the control group was very low (<0.001 mg/g). Supplementation of squalene in the diet significantly 
elevated its level in the liver. Supplementation of 0.05% SLO also led to accumulate squalene in the 
liver to a level that was similar to or higher than the 0.1% squalene group. A similar squalene pattern 
was also observed in the adipose tissue among the five groups. No differences in heart squalene levels 
were observed among the control and tested hamsters. This study shows that squalene and SLO are 
hypercholesterolemic at least in hamsters recommend caution when squalene or SLO are routinely 
consumed as health supplements. 
Burford et al. [77] compared various dose levels of batyl alcohol and selachyl alcohol with the 
known anti-inflammatory treatments aspirin (acetylsalicylic acid) phenylbutazone and hydrocortisone 
in rats. Both AKG had significant anti-inflammatory activity; the ant-inflammatory effects of the AKG 
were only effective when administered orally; when given by injection either into the peritoneum or 
directly into the inflammatory site, they were ineffective; on a dose for dose basis, both AKG were 
much more effective than aspirin, more potent that phenylbutazone and equally as effective as 
hydrocortisone when they were both in the lower dose range.  
4. Conclusions 
Sharks seem to be protected from developing cancer, but the reason is yet not understood. SLO is 
the major source of AKG, glycerol ether lipids which have been widely used in the past years in the 
Scandinavian medicine because of their properties as immunity boosters and a remedy against 
radiation therapy and cancer. We have found several clinical trials involving the use of AKG and their 
ability to bring several benefits to the immunitary system. Among the most interesting properties of 
AKG, the administration of small amounts (10–100 ng) of these compounds in mice has enhanced 
macrophage activation for Fc-mediated ingestion activity at the 5th day post treatment [27] and it has 
partially inhibited PAF-induced platelet stimulation possibly interfering with PAF receptors [30]. 
Moreover a study shows that a 30 min in vitro treatment of peritoneal cells with synthetic DDG has 
resulted in a greatly enhanced Fc-receptor-mediated ingestion activity of macrophage adherent cells 
[31]. A study [32] has shown that AKG are able to increase [Ca
2+]i influx in human Jurkat T-cells 
possibly by modulating the permeability of calcium channels.  Mar. Drugs 2010, 8  
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It has been hypothesized that the shark c-myc gene, which is located on the long harm of 
chromosome 8 in humans, can be inactive or covered [78]. Both reductions of c-myc and inappropriate 
over expression can be associated with cellular apoptosis and part of the oncogenic process enhancing 
cell proliferation and inhibition of cell differentiation. The authors did not obtain the sequence for that 
gene and observed some level of pigment with a background for the sequence. It has also been 
demonstrated that AKG are able to induce high IL-12 level, a key cytokine for the activation of Th1 
responses [34]. 
In addition the intake of a mixture of CA, BA, M-BA and methoxy-substituted alkyl lipids has been 
shown to reduce the 5-year cervical cancer mortality and also the radiation-induced neutropenia; the 
same study has underlined that ether lipids increase blood concentrations of neutrophils and enhance 
antibody formation [35].  
An increased response of neutrophils towards bacteria, an increased level of C4 component of 
complement in blood, the rise of total antioxidant status of serum, and the predominance of Type 1 
cytokine IFN-gamma, TNF-α and IL-2 production by peripheral blood mononuclear cells after SLO 
intake have also been observed [36]. A study [37] carried out on 10 adult healthy volunteers treated 
with AKG per os for one month, has demonstrated an increase of C1q level and CD4/CD8 ratio from 
1.3 to 1.8 and polarized Th1/Th2 lymphocyte cytokine secretion towards Th1. On the contrary no 
effect on CD4
+CD25
+ regulatory lymphocytes was observed; due to the absence of any side effects this 
innate immunity supporting agent was stated to be safe and effective.  
In the oncological area it has been observed that AKG, orally administered to mice affected by 
Lewis lung carcinoma tumors, have reduced metastasis dissemination by 64 ± 8%, whereas SLO effect 
has been 30 ± 9% below control [41]. Purified AKG have also decreased significantly plasmalogen 
content in tumors, whereas SLO has had no such effect. A 5-day treatment with AKG has reduced the 
presence of von Willebrand factor in tumors emphasizing the anti-angiogenic effect of this compound.  
Another experimental study in mice with syngeneic L-1 sarcoma has shown that SLO and fish liver 
oil together with arctic birch ashes are able to significantly reduce cutaneous angiogenesis induced by 
tumor cells and tumor growth [42]. 
The injection of different amounts of SLO in mice at the concentrations of 50 and 10 mg/kg/day, 
have had maximum DTH response in 48 hours; the percentage of CD8
+ lymphocytes have increased in 
the mice injected with SLO; SLO (10 mg/kg/day) injected intraperitoneally has shown a slight non 
significant decrease of tumor growth rate and in addition SLO injection caused a significant increase in 
IFN-gamma production [43].  
Both human prostate cancer LnCap and DU145 cell lines have responded to the antiproliferative 
effect of MHG in a similar manner [48]. 
Furthermore, a clinical trial [66] of radiotherapy for uterine cervical cancers has shown a decrease 
in cancer growth as well as in the number of both radiation and complex injuries due to AKG   
pre-radiation treatment; prophylactic AKG administration has dramatically reduced vescical fistulas 
thus confirming the complementary role of these compounds in supporting the patients against 
radiotherapy toxicity. 
Summarizing, the putative milestones of AKG anticancer effects are mainly their property to 
activate macrophages and to increase the production of cytokines such as IL-12 and IFN-gamma; IL-12 
promotes secretion of IFN-gamma from naive and activated T and NK cells, enhances the cytotoxic Mar. Drugs 2010, 8  
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activity of NK cells, cytotoxic T lymphocytes, lymphokine activated killer cells and increases the 
proliferation of preactivated T cells and NK cells [51,52]. The anticancer effect of AKG is also 
supported by the O-alkyl groups storage found into cancer cells that display a low or absent expression 
of O-alkyl monooxygenase enzyme activity as they are unable to face the abnormal distribution of 
these glyceryl ether lipids [53,54]. 
Some studies support that AKG could represent, in the future, a new therapeutic agent to overcome 
the limited access of pharmacological agents for the CNS; in fact it has been shown [58] that 
intracarotid short-chain AKG constitute a very effective and low toxic strategy for transient opening of 
the BBB to overcome the limited access of cytotoxic drugs to the brain; nowadays the modern   
echo- and angiographic techniques represent a simple and safe way to study the carotid artery lumen, 
and the use of powerful effective toxic chemotherapeutic agents, in a reduced concentration, could be 
an important therapeutical choice in the management of primary and secondary brain cancers. 
This puzzling locoregional approach has never been attempted in humans yet but it is worthy of 
consideration and attention. Other in vitro and experimental investigations using DDG formulations in 
bacteria and fungi are encouraging for a clinical widespread use against bacterial and fungal 
infections. Although the studies reported in this review encourage the AKG clinical use, we have not 
reached the evidence based confirmation yet. Since a study [76] in hamsters has shown that squalene 
and SLO are hypercholesterolemic, caution should be recommended when squalene or SLO are 
routinely consumed and more studies should be designed to point out if these effects may occur in 
human subjects. 
Although further randomized clinical trials, involving larger cohorts of patients, are required to 
finally confirm the properties of these molecules and to definitely exclude possible side effects, a 
spontaneous anedoctical use of these compounds is strongly recommended, especially on a 
prophylactic perspective. 
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